REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 AAN 2017: There is a growing body of data on the use of disease-modifying therapies in patients with progressive multiple sclerosis. The following is a summary of key studies presented at AAN 2017.
Ocrelizumab: In the phase III ORATORIO trial in primary-progressive MS, a significantly lower proportion of patients had 24-week confirmed disability progression with ocrelizumab 600 mg q24 weeks versus placebo (32.9% vs. 39.3%; 24% reduction) (Montalban et al. N Engl J Med 2017;376:209-220). A new analysis of ORATORIO examined a novel composite measure, NEPAD (for no evidence of progression or active disease), from baseline to week 120 (Wolinsky et al. AAN 2017; abstract P4.384).